相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning
Navneet S. Majhail et al.
BLOOD (2011)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M. Kantarjian et al.
BLOOD (2011)
Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
Mariana Serpa et al.
ACTA HAEMATOLOGICA (2010)
Uncommon case of chronic myeloid leukemia with multiple myeloma
Masaru Ide et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Solid cancers after allogeneic hematopoietic cell transplantation
J. Douglas Rizzo et al.
BLOOD (2009)
Imatinib for refractory chronic graft-versus-host disease with fibrotic features
Attilio Olivieri et al.
BLOOD (2009)
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti et al.
BLOOD (2009)
Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature
Salvatore Guastafierro et al.
LEUKEMIA RESEARCH (2009)
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
R. Seggewiss et al.
CYTOTHERAPY (2008)
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling
J. Chen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Hagop Kantarjian et al.
BLOOD (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies
C. Ferry et al.
BONE MARROW TRANSPLANTATION (2007)
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Andrew E. Grulich et al.
LANCET (2007)
Chronic myeloid leukemia:: Diagnosis and treatment
Alfonso Quintas-Cardama et al.
MAYO CLINIC PROCEEDINGS (2006)
Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib
PR Pilot et al.
LEUKEMIA (2006)
Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia
L Roy et al.
LEUKEMIA (2005)
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase - Comparison with historic data
HM Kantarjian et al.
CANCER (2003)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
